^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Bladder cancer: Second-line systemic therapy for locally advanced or metastatic disease (Stage IV) (post-platinum)...Preferred regimen...Pembrolizumab
